Carbadox

Carbadox is a quinoxaline-di-N-oxide antibiotic compound which is widely fed to nursery-age pigs to control enteric diseases and improve feed efficiency.

Product information

CAS Number: 6804-07-5

Molecular Weight: 262.22

Formula: C11H10N4O4

Chemical Name: 4-hydroxy-3-({[(methoxycarbonyl)imino]amino}methylidene)-3,4-dihydroquinoxalin-1-ium-1-olate

Smiles: COC(=O)N=NC=C1C=[N+]([O-])C2=CC=CC=C2N1O

InChiKey: BPMVRAQIQQEBLN-JQAHBYNNSA-N

InChi: InChI=1S/C11H10N4O4/c1-19-11(16)13-12-6-8-7-14(17)9-4-2-3-5-10(9)15(8)18/h2-7,18H,1H3/b8-6+,13-12+

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 3.57 mg/mL (13.61 mM; Need ultrasonic). H2O : < 0.1 mg/mL (insoluble).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

The results of MTT assay demonstrate a dose-dependent decrease in mitochondrial activity in Vero cells at all concentrations of Carbadox. Treatment with Carbadox at the highest concentration of 160 μg/mL results in cell viability down to only 12%. Cells following Carbadox treatment show a dose-dependent increase of the DNA migration (p<0.01). The nuclear division index (NDI) reduces markedly with the increase doses of Carbadox.

In Vivo:

Alpha diversities (Shannon diversity, Heips evenness, and inverse Simpson indices) of samples from medicated piglets compare to non-medicated piglets are significantly different at 2, 3, and 4 days after continuous Carbadox, but not different in either late Carbadox or at any time during the withdrawal period. Analysis of the community structure of bacteria in animals shows significant differences at days 3 and 4 of early Carbadox treatment ([R=0.32, p=0.015] and [R=0.54, p=0.003], respectively), but not before starting antibiotic treatment (p=0.82). No significant differences in E. coli colony forming units (CFUs) are observed during the Carbadox-treatment period of the study or late in the withdrawal period. E. coli CFUs are significantly different between the medicated and non-medicated groups on day 2 after the withdrawal of Carbadox.

Products are for research use only. Not for human use.